Argentina
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
 | This article is a stub. |
Argentina
Medical guidelines
National health department
Government health insurance
Private health insurance
Access to care
Ampligen (rintatolimod) has been approved for use by the Argentine Republic for severe ME/CFS as of August 23, 2016.[1]
Social security and disability benefits
Patient charities
Research
Research groups
Researchers
Clinicians
Notable patients
Deceased patients
Learn more
See also
References
- ↑ Inc., Hemispherx Biopharma (August 23, 2016). "Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic". GlobeNewswire News Room. Retrieved August 12, 2018.
